Tazocin Intervention Study
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Infections
Intervention: Tazocin (Piperacillin/Tazobactem) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
1. To determine the value of using piperacillin/tazobactam in reducing the cases of
extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae
colonization and infection.
2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both
pre-and post-intervention in the selected medical centers.
Clinical Details
Official title: Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
Secondary outcome: The infection rate due to ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients admitted or transferred to the ICU/pulmonary/Infection units
- Patients of either sex, 18 years of age or older Patients who stay in units less than
48 hours will not be enrolled.
Locations and Contacts
Peking 100730, China
Additional Information
Starting date: September 2006
Last updated: December 7, 2007
|
